Seoul National University Hospital
Seoul, South Korea
NCT Number: NCT00938197
To evaluate the pharmacokinetic drug interaction after oral concurrent administration of fimasartan and amlodipine in healthy male volunteers
Looking for future studies?
Notify Me20 year–40 year
Male
Interventional
Phase 1
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Fimasartan (1d~7d) Amlodipine (12d~14d) Fimasartan + Amlodipine(15d~21d)
Amlodipine (1d~10d) Amlodipine (25d~27d) Fimasartan + Amlodipine(28d~34d)
Time frame: Part A: 0, 0.5, 1, 1.5, 2, 2.5 3, 4, 6, 8, 12, 24 hours at 7 day and 21 day Part B: 0, 1, 3, 4, 5, 6, 7, 8, 9, 11, 13, 15, 24 hours at 10 day and 34 day
Boryung Pharmaceutical Co., Ltd
Industry
An Open-label, Multiple-dosing, and Crossover Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07704697
Cardiovascular Diseases, Essential Hypertension
Beijing, Beijing Municipality, China
View Trial DetailsNCT07704684
Cardiovascular Diseases, Essential Hypertension
Beijing, Beijing Municipality, China
View Trial DetailsNCT07700875
Cardiovascular Diseases, Essential Hypertension
Jinan, Shangdong, China
View Trial DetailsNCT05503953
Cardiovascular Diseases, Essential Hypertension
Seoul, South Korea
View Trial Details